Peristomal psoriasis: an extraintestinal manifestation of inflammatory bowel disease?

Abdelmaksoud, Ayman

doi:10.1111/ijd.13987

Cited by 2 publications

(2 citation statements)

References 9 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, there are case reports of an association between LABD and psoriasis . An underlying immune cluster linking BP, LABD, psoriasis, multiple sclerosis (MS), and irritable bowel disease (IBD) is increasingly being recognized suggesting, that the pathogenesis of AIBD in the setting of psoriasis is beyond epitope spreading due to chronic skin inflammation …”

Section: Discussionmentioning

confidence: 99%

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Gibson

Amber

2019

Int J Dermatology

View full text Add to dashboard Cite

Background To investigate the clinical course of autoimmune blistering diseases (AIBDs) following treatment with biologic agents (BAs) for chronic inflammatory diseases.Methods A comprehensive review of available, published literature was performed using PubMed and CINAHL search engines. Diagnostic criteria of AIBD included positive direct immunofluorescence studies and/or positive serology with clinically suggestive features.Results A total of 22 cases of AIBDs provoked by the use of BAs were found. The most commonly implicated agents were tumor necrosis factor-alpha inhibitors (n = 14). The mean age of onset of AIBD was 59.4 years (median 61.5 years, range 31-82). Average time to onset of AIBD following initiation of the suspected BA was 33.7 AE 43.8 weeks (range 3 days to 152 weeks). Psoriasis was the most common associated condition for which the BA was prescribed (n = 11), followed by rheumatoid arthritis (n = 6) and ulcerative colitis (n = 5). Of the 21 cases reporting AIBD outcome, 17 reported remission or complete resolution upon stopping treatment with the involved BA. Four cases reported continued bullae formation without worsening of disease following cessation of the BA or systemic corticosteroids used to treat the AIBD. Five cases rechallenged the patient with the involved BA and four of the five reported recurrence, often with quicker onset and more severe symptoms.Conclusions BAs may be suspected in patients developing AIBD while being treated for chronic inflammatory diseases. A majority of cases resolve upon cessation of the offending agent.

show abstract

Section: Discussionmentioning

confidence: 99%

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Gibson

Amber

2019

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…In general, patients with stomata can occasionally develop peristomal skin disease such as fecal or urinary irritant reaction/dermatitis, bacterial or fungal infections, chronic papillomatous dermatitis, rarely psoriasis, and others . Intestinal metaplasia around a stoma has been reported as one of the complications associated with stomata .…”

mentioning

confidence: 99%

A rare skin disorder associated with a stoma: intestinal metaplasia and adenoma occurring in a skin ulcer around a colostomy site

2019

View full text Add to dashboard Cite

Peristomal psoriasis: an extraintestinal manifestation of inflammatory bowel disease?

Cited by 2 publications

References 9 publications

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

Autoimmune blistering diseases provoked during the treatment of chronic inflammatory disease with biologic agents: a systematic review

A rare skin disorder associated with a stoma: intestinal metaplasia and adenoma occurring in a skin ulcer around a colostomy site

Contact Info

Product

Resources

About